Introduction Scaling Poly(lactic-co-glycolic acid) PLGA Microsphere Manufacturing from a 1g laboratory bench batch to a 500g cGMP-compliant pilot scale requires […]
Introduction: Peptide-Oligonucleotide Conjugates for Blood-Brain Barrier Delivery are being explored because conventional oligonucleotides generally struggle to reach therapeutic concentrations in
Introduction Poly(lactic-co-glycolic acid) PLGA Nanoparticle Development offers an advanced biomaterial platform for the encapsulation, stabilization, and delivery of fragile subunit
Introduction The Accuracy and Precision Requirements for a Validated Bioanalytical Method define the quantitative performance limits that analytical assays must
What Are the Accuracy and Precision Requirements for a Validated Bioanalytical Method? Read More »
Introduction The fundamental distinction between a fit-for-purpose and a fully validated bioanalytical method is determined by the extent of experimental
Introduction: Choosing between analytical platforms is an important decision in biologic drug development because the assay ultimately determines what is
When Should You Use a Ligand Binding Assay Instead of LC-MS/MS for a Biologic Drug? Read More »
Introduction Quantitative NMR (qNMR) for peptide reference standard characterization is an increasingly important analytical approach for establishing the quantitative content,
Introduction: Understanding biosimilar vs biologic is important for pharmaceutical companies developing follow-on biological products, researchers evaluating biologic comparability, and healthcare
What is the Difference Between a Biosimilar and a Biologic? Read More »
Introduction: The FDA Regulatory Pathway for Peptide-Oligonucleotide Conjugates is not determined simply by identifying a product as either a peptide
What FDA Regulatory Pathway Applies to Peptide-Oligonucleotide Conjugate Therapeutics? Read More »
Introduction: For any company preparing to file an Abbreviated New Drug Application (ANDA), a Comparative Dissolution Study for ANDA is
